Drugs Xagena
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada and Japan under the brand name Lorbrena ), as a monotherapy for ...
The FDA ( U.S. Food and Drug Administration ) has approved supplemental New Drug Application ( sNDA ) for Lorbrena ( Lorlatinib ), a tyrosine kinase inhibitor ( TKI ), expanding the indication to incl ...
The European Commission ( EC ) granted marketing authorization for Lorviqua ( Lorlatinib, available in the U.S. under the brand name Lorbrena ) as monotherapy for the treatment of adult patients with ...
